Skip to main content
. 2022 Nov 14;20:6403–6411. doi: 10.1016/j.csbj.2022.11.025

Fig. 3.

Fig. 3

Validation of CAFs heterogeneity in the TME of ovarian cancer based on the additional scRNA-seq datasets. (A) UMAP plot (left) of profiled cell clusters signature distribution plot (right) of CAFs subtype signature genes based on the scRNA-seq dataset of 7 high-grade serous tubo ovarian cancer samples. (B) UMAP plot (left) of profiled cell clusters signature distribution plot (right) of CAFs subtype signature genes based on the scRNA-seq dataset of 6 metastatic ovarian cancer samples.